Besponsa (Inotuzumab ozogamicin) for Leukemia

Overview
Besponsa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat relapsed or refractory cases of B-cell precursor acute lymphoblastic leukemia (ALL) in adults. Besponsa is also known by its drug name, inotuzumab ozogamicin.

Besponsa is an antibody-drug conjugate consisting of two parts. Inotuzumab is a biologic drug that targets the CD22 protein on B cells. Ozogamicin is a powerful anticancer drug too toxic to be administered on its own. In combination, the two molecules are believed to deliver the drug directly to B cells, where it causes cell death.

How do I take it?
Besponsa is administered as an intravenous injection on three specific days of a 21-day cycle.

Besponsa comes in the form of a single-dose vial.

Side effects
The FDA-approved label for Besponsa lists common side effects including fever, fatigue, headache, nausea, abdominal pain, abnormal bleeding, low blood cell counts, and infections.

Rare but serious side effects listed for Besponsa can include severe and life-threatening liver damage, dangerous infections, infusion reactions, fetal harm in pregnant women, and increased risk of death in people who have received a stem cell transplant.

For more details about this treatment, visit:

Besponsa — Pfizer
https://www.besponsa.com

ALL: Relapsed and Refractory — Leukemia & Lymphoma Society
https://www.lls.org/leukemia/acute-lymphoblasti...